Furthermore, Du’s group suggested that PKCι may serve as a novel therapeutic target for CRC because its inhibition reduces epithelial–mesenchymal transition (EMT), migration, and invasion of CRC cells by suppressing the Rac1-JNK pathway [159]. This evidence concerns the gene PRKCA and colorectal carcinoma.